1 / 21

“What I Do”

“What I Do”. Bryan Betz PhD Clinical Assistant Professor Technical Director Molecular Diagnostics Laboratory. Molecular Diagnostics / Molecular Pathology. Application of molecular biology techniques and knowledge to clinical laboratory diagnosis. Infectious disease Inherited disease

Lucy
Download Presentation

“What I Do”

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. “What I Do” Bryan Betz PhD Clinical Assistant Professor Technical Director Molecular Diagnostics Laboratory

  2. Molecular Diagnostics / Molecular Pathology Application of molecular biology techniques and knowledge to clinical laboratory diagnosis • Infectious disease • Inherited disease • Hematopathology • Solid Tumors • Identity Testing • Forensics • Pharmacogenomics Is and will continue to revolutionize the way in which diseases are diagnosed and therapeutics are employed

  3. Molecular Pathology A Universal Discipline of Laboratory Medicine INFECTIOUS DISEASE FORENSICS HEMATO PATHOLOGY Molecular Pathology IDENTITY TESTING SOLID TUMORS GENETIC DISEASE

  4. Molecular Diagnostics is a Rapidly Expanding Field • Molecular diagnostics is the fastest growing segment of the diagnostics industry • ~$34 billion world-wide market • 6-8% annual growth • New discoveries and technology platforms are leading to the development of more and increasingly sophisticated tests • DNA sequencing • Expression microarrays • Array CGH • Detection technology/test platforms • Majority of the innovation and discovery takes place in Universities

  5. UM Molecular Diagnostics Test Volume and TATJan 2002 – Dec 2009

  6. Applications of Molecular Diagnostics in Clinical Laboratory Medicine • Infectious Disease • Qualitative and quantitative detection • Microbial identification • Drug resistance • Identity Testing • Determining familial relationships • Bone marrow engraftment analysis • GVHD monitoring • Laboratory specimen identification • Forensics • Genetics (inherited disease) • Diagnosis of: • Single gene disorders • Complex polygenic disorders • Chromosomal disorders • Oncology – Solid Tumor and Hematologic • Diagnosis • Prognosis • Predict response to therapy • Monitor residual disease • Pharmacogenomics • Drug metabolism • Determine drug dosage

  7. UM Molecular Diagnostics Test Menu Hematologic Malignancies Quantitative BCR/ABL BCR/ABL1 Kinase Mutation Analysis FLT3 Gene Mutation NPM1 Mutation CEBPA Mutation KIT D816V Mutation t(15;17) PML/RARA Translocation t(14;18) IGH/BCL2 Translocation B Cell (IGH) Gene Rearrangement T Cell Gamma (TRG) Gene Rearrangement JAK2 V617F Mutation Detection JAK2 Exon 12 Mutations (March 2010) Solid Tumors PAX/FOXO1 Translocation, Alveolar Rhabdomyosarcoma EWSR1/WT1 Translocation, DSRT EWS/FLI1, EWS/ERG Translocations, Ewing Sarcoma SYT/SSX Translocation, Synovial Sarcoma EWS/ATF1 Translocation, Clear Cell Sarcoma Microsatellite Instability Analysis KRAS Mutation BRAF V600E Mutation KIT Mutation in GIST KIT Mutation in Melanoma HER2 FISH, Breast cancer UroVysion FISH, Bladder cancer Genetics/Pharacogenomics Cystic Fibrosis Carrier Screening Apolipoprotein E Genotyping Hereditary Hemochromatosis Mutation Detection Factor V Leiden Mutation Detection Methylenetetrahydrofolate Reductase C677T Mutation Prothrombin 20210 Mutation UGT1A1 Promoter Genotyping Warfarin Sensitivity Analysis Identity Testing Bone Marrow Transplant Engraftment Analysis

  8. My Day to Day Activities • Clinical • • Direct the development, validation, and implementation of new molecular tests • • Technical oversight and trouble shooting of existing tests • • Maintain quality control and quality assurance standards • • Daily review of test data • Teaching • • MGP fellows and block E residents • Research/Academic • • Novel molecular diagnostic tests and technologies • • Collaborations with AP and HP faculty

  9. New Tests Since July 2007 Hematologic Malignancies Quantitative BCR/ABL BCR/ABL1 Kinase Mutation Analysis FLT3 Gene Mutation NPM1 Mutation CEBPA Mutation KIT D816V Mutation t(15;17) PML/RARA Translocation t(14;18) IGH/BCL2 Translocation B Cell (IGH) Gene Rearrangement T Cell Gamma (TRG) Gene Rearrangement JAK2 V617F Mutation Detection JAK2 Exon 12 Mutations (March 2010) Solid Tumor PAX/FOXO1 Translocation, Alveolar Rhabdomyosarcoma EWSR1/WT1 Translocation, DSRT EWS/FLI1, EWS/ERG Translocations, Ewing Sarcoma SYT/SSX Translocation, Synovial Sarcoma EWS/ATF1 Translocation, Clear Cell Sarcoma Microsatellite Instability Analysis KRAS Mutation BRAF V600E Mutation KIT Mutation in GIST KIT Mutation in Melanoma HER2 FISH, Breast cancer UroVysion FISH, Bladder cancer Genetics/Pharacogenomics Cystic Fibrosis Carrier Screening Apolipoprotein E Genotyping Hereditary Hemochromatosis Mutation Detection Factor V Leiden Mutation Detection Methylenetetrahydrofolate Reductase C677T Mutation Prothrombin 20210 Mutation UGT1A1 Promoter Genotyping Warfarin Sensitivity Analysis Identity Testing Bone Marrow Transplant Engraftment Analysis

  10. Molecular Diagnostics - Oncology Diagnosis Prognosis Predict response to therapy Monitor residual disease

  11. Diagnosis – Ewing Sarcoma Reverse transcription cDNA EWSR1 primer FLI1 primer PCR Extract RNA EWSR1/FLI1 ~ 1 billion copies of target cDNA

  12. PCR products Detection Capillary electrophoresis EWSR1/FLI1 (Type 1) GAPDH control

  13. Molecular Diagnostics - Oncology Diagnosis Prognosis Predict response to therapy Monitor residual disease

  14. Prognosis - Normal Karyotype AML CEBPAmut NPM1mutFLT3-ITDneg Other genotypes Schlenk RF et al. NEJM 358(18):1909, 2008

  15. Prognostic Molecular Testing in AML – The UM Experience Tests per Month 2004 2005 2006 2007 2008 2009

  16. Molecular Diagnostics - Oncology Diagnosis Prognosis Predict response to therapy Monitor residual disease

  17. Predict Response to Therapy: KIT Mutations in Melanoma (4 wk) Hodi FS et al., 2008 J Clin Oncol 26(12):2046

  18. Molecular Diagnostics - Oncology Diagnosis Prognosis Predict response to therapy Monitor residual disease

  19. Monitoring Residual Disease – UroVysion FISH Malignant Urothelial Cell Normal Urothelial Cell CEP 3 LSI 9p21 CEP 7 CEP 17

  20. Monitoring Residual Disease – UroVysion FISH Case 4 History of CIS (bladder), Post Resection Recurrence of CIS, BCG therapy, Monitoring Cystoscopy - Negative FISH - Positive

  21. Thanks!

More Related